Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Synonyms
Apixaban
apixabán
apixabanum
Brand Names
Sandoz Apixaban Tablet
Riva Apixaban
Apixaban Accord
Pro-apixaban
Taro-apixaban
Apo-apixaban
Nra-apixaban
Nat-apixaban
Teva-apixaban
Sandoz Apixaban Sdz
Ach-apixaban
Eliquis
Ag-apixaban
ELIQUIS 30-Day Starter Pack
Mint-apixaban
Jamp Apixaban
Mar-apixaban
Apixaban
Auro-apixaban
M-apixaban
Bio-apixaban
Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682